Drug Trial Radar · NCT01357603
Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM
Last checked: Nov 20, 2026Latest source record: Jan 25, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
111
Actual
Start
Jun 2011
Primary completion
May 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- WockhardtIndustry
- Sponsor type
- Industry
- First posted
- May 20, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Health services research
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this trial is to demonstrate bioequivalence of Glaritus® to Lantus® with regard to its total and to its maximum serum insulin concentrations.
Conditions
- Type1 Diabetes
Interventions
GlargineBiological
dosage form: Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bioequivalence based on Pharmacokinetic parameter:AUC INS-GLR 0-24h.Time frame: over 24hrs post dose
- Bioequivalence based on Pharmacodynamic parameter: AUC GIR 0-24hrsTime frame: over 24hrs post dose
- Pharmacokinetic Parameters: Maximum concentration (Cmax)Time frame: over 24hrs post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Profil Institute for clinical Research
Chula Vista, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.